Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Genes, erbB-1”

113 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 113 results

Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Not applicableUnknownNCT02328391
What this trial is testing

STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE

Who this might be right for
Carcinoma, Squamous Cell
Grupo Gallego de Cancer de Pulmon 51
Early research (Phase 1)Study completedNCT03846310
What this trial is testing

Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer MetastaticNon Small Cell Lung CancerNonsquamous Nonsmall Cell Neoplasm of Lung+1 more
Arcus Biosciences, Inc. 77
Large-scale testing (Phase 3)Active Not RecruitingNCT04695925
What this trial is testing

Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

Who this might be right for
Non-small Cell CarcinomaEGFR Gene Mutation
Li Zhang, MD 294
Not applicableNot Yet RecruitingNCT06117644
What this trial is testing

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIA+1 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 30
Testing effectiveness (Phase 2)Looking for participantsNCT04322890
What this trial is testing

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationALK Gene Mutation+2 more
Hunan Province Tumor Hospital 6,000
Testing effectiveness (Phase 2)UnknownNCT01749072
What this trial is testing

Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients

Who this might be right for
Non-small Cell Lung CancerEffects of Chemotherapy
Peking Union Medical College Hospital 120
Testing effectiveness (Phase 2)Study completedNCT01204307
What this trial is testing

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

Who this might be right for
Advanced Non-Squamous Non-Small Cell Lung Cancer
Chang Gung Memorial Hospital 101
Testing effectiveness (Phase 2)UnknownNCT04882345
What this trial is testing

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Who this might be right for
Lung CancerEGFR Gene Mutation
Shanghai Chest Hospital 40
Not applicableUnknownNCT06291688
What this trial is testing

Applying Mobile Healthcare Education to Improve Cutaneous Self-care Capability

Who this might be right for
EGFR Gene MutationDrug-Related Side Effects and Adverse ReactionsCancer, Treatment-Related+1 more
National Taiwan University Hospital 110
Testing effectiveness (Phase 2)UnknownNCT04358562
What this trial is testing

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Who this might be right for
Non-small Cell Lung CancerEGFR Gene Mutation
Second Affiliated Hospital of Nanchang University 240
Testing effectiveness (Phase 2)Study completedNCT03888092
What this trial is testing

Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification

Who this might be right for
Esophageal Squamous Cell Carcinoma
Sunshine Lake Pharma Co., Ltd. 81
Not applicableActive Not RecruitingNCT05370469
What this trial is testing

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Who this might be right for
Lung CancerEGFR Gene MutationEGFR+6 more
University of Virginia 30
Not applicableStudy completedNCT04640870
What this trial is testing

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Who this might be right for
Non Small Cell Lung CancerEGF-R Positive Non-Small Cell Lung CancerEGFR Gene Mutation
Hellenic Cooperative Oncology Group 59
Testing effectiveness (Phase 2)Looking for participantsNCT07548060
What this trial is testing

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

Who this might be right for
NSCLC Stage IVEGFR Gene Mutation
Tianjin Medical University Cancer Institute and Hospital 25
Early research (Phase 1)Study completedNCT06525246
What this trial is testing

Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

Who this might be right for
Stage IIIB Non-small Cell Lung CancerStage IIIC Non-Small Cell Lung CancerStage IV Non-small Cell Lung Cancer+2 more
Ono Pharmaceutical Co., Ltd. 78
Large-scale testing (Phase 3)UnknownNCT02886195
What this trial is testing

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

Who this might be right for
EGFR Gene Mutation
Fujian Cancer Hospital 120
Early research (Phase 1)Ended earlyNCT03065387
What this trial is testing

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Who this might be right for
Advanced Malignant Solid NeoplasmEGFR Gene AmplificationEGFR Gene Mutation+7 more
M.D. Anderson Cancer Center 84
Large-scale testing (Phase 3)Study completedNCT02151981
What this trial is testing

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Anticancer Treatment
AstraZeneca 421
Not applicableLooking for participantsNCT05598528
What this trial is testing

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

Who this might be right for
Lung Cancer, Non-small CellEGFR Gene MutationEGFR-TKI Resistant Mutation+2 more
Second Xiangya Hospital of Central South University 210
Next Page